Description
Recombinant Human CD20/MS4A1 Protein (aa 213-297, His Tag) | PKSH031312 | Gentaur US, UK & Europe Disrtribition
Synonyms: B1;Bp35;CD20;CVID5;LEU-16;MS4A1;MS4A2;S7
Active Protein: N/A
Activity: A DNA sequence encoding the human CD20 (NP_068769.2) (Glu213-Pro297) was expressed; with an N-terminal polyhistidine tag.
Protein Construction: A DNA sequence encoding the human CD20 (NP_068769.2) (Glu213-Pro297) was expressed; with an N-terminal polyhistidine tag.
Fusion Tag: N-His
Species: Human
Expressed Host: HEK293 Cells
Shipping: This product is provided as lyophilized powder which is shipped with ice packs.
Purity: > 83 % as determined by reducing SDS-PAGE.
Endotoxin: < 1.0 EU per µg as determined by the LAL method.
Stability and Storage: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months.
Molecular Mass: 12.1 kDa
Formulation: Lyophilized from sterile PBS, pH 7.4
Reconstitution: Please refer to the printed manual for detailed information.
Background: CD20 (membrane-spanning 4-domains; subfamily A; member 1); also known as MS4A1; is a member of the membrane-spanning 4A gene family. Members of this nascent protein family are characterized by common structural features and similar intron/exon splice boundaries and display unique expression patterns among hematopoietic cells and nonlymphoid tissues. CD20 / MS4A1 is expressed on all stages of B cell development except the first and last. CD20 / MS4A1 is present from pre-pre B cells through memory cells; but not on either pro-B cells or plasma cells. It is a B-lymphocyte surface molecule which plays a role in the development and differentiation of B-cells into plasma cells. CD20 / MS4A1may be involved in the regulation of B-cell activation and proliferation. Defects in CD20 / MS4A1 are the cause of immunodeficiency common variable type 5(CVID5). CVID5 is a primary immunodeficiency characterized by antibody deficiency; hypogammaglobulinemia; recurrent bacterial infections and an inability to mount an antibody response to antigen. The defect results from a failure of B-cell differentiation and impaired secretion of immunoglobulins; the numbers of circulating B-cells is usually in the normal range; but can be low.Immune Checkpoint Immunotherapy Cancer Immunotherapy Targeted Therapy
Research Area: Cancer, immunology, Stem cells
